Acute Myeloid Leukemia (AML)
Evaluating safety, tolerability and efficacy of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory Acute Myeloid Leukemia (AML) patients.
Status: RECRUITMENT STARTING Q3’2023
To learn more about this study, please visit ClinicalTrials.gov
For more information on AML, please visit LSS.org
For more information on MDS, please visit LSS.org